1. Home
  2. GENK vs INTS Comparison

GENK vs INTS Comparison

Compare GENK & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

HOLD

Current Price

$1.68

Market Cap

12.8M

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.02

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENK
INTS
Founded
2011
2012
Country
United States
United States
Employees
2700
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
13.7M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GENK
INTS
Price
$1.68
$4.02
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
$4.50
$38.00
AVG Volume (30 Days)
43.3K
24.2K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
1.88%
N/A
EPS Growth
62.50
N/A
EPS
N/A
N/A
Revenue
$208,380,000.00
N/A
Revenue This Year
$4.79
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.12
N/A
52 Week Low
$1.43
$0.22
52 Week High
$3.21
$8.06

Technical Indicators

Market Signals
Indicator
GENK
INTS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GENK
INTS

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: